Showing 15 posts of 17 posts found.


Ex-Novartis employee found not guilty of deceitful drug advertising

March 17, 2017
Medical Communications, Sales and Marketing Diovan, Novartis, legal

A Tokyo court has ruled finding ex-Novartis employee Nobuo Shirahashi and the company’s Tokyo-based sales arm Novartis Pharma KK not …

Novartis image

Novartis sales below forecast in ‘transformative’ year

January 28, 2015
Sales and Marketing Diovan, Exforge, Gleevec, Jimenez, Novartis, amlodipine, q4, valsartan

Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …

Novartis heart drug sees stellar results

September 1, 2014
Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan

Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …

novartis image

Novartis faces data fraud charges in Japan

July 3, 2014
Medical Communications, Sales and Marketing Diovan, Japan, Novartis, data, fraud, heart, valsartan

Novartis is facing criminal charges in Japan over the alleged falsifying of data for its once big-selling heart drug Diovan. …

Diovan image

Ranbaxy’s Diovan copycat approved in US

June 27, 2014
Manufacturing and Production, Sales and Marketing Diovan, FDA, Novartis, Ranbaxy, blood pressure, sun pharmaceuticals, valsartan

Ranbaxy has won approval for its copycat form of Novartis’ blockbuster blood pressure drug Diovan, as the Swiss firm finally …

Police raid Novartis Tokyo office

February 20, 2014
Medical Communications, Sales and Marketing Diovan, Japan, Novartis, tokyo

Authorities in Japan have raided the premises of Novartis’ Tokyo operation as part of an ongoing investigation into the promotion …

Novartis may axe 1,000 jobs in Diovan wake

January 23, 2014
Manufacturing and Production, Sales and Marketing Coartem, Diovan, Novartis, cuts

Novartis will shut down a plant in New York State that made heart drug Diovan and malaria treatment Coartem as …

Novartis image

Novartis faces Japan probe

January 10, 2014
Sales and Marketing Diovan, Japan, Novartis

Novartis is under pressure in Japan where authorities are looking at the way the Swiss firm promoted its blood pressure …

Novartis image

Novartis sees profit slip

October 23, 2013
Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya

Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …

Novartis image

Diovan trials may have been run by Novartis staff

May 29, 2013
Research and Development, Sales and Marketing Diovan, Novartis

Several post-marketing clinical trials of the blockbuster blood pressure drug Diovan may have been run by employees of the drug’s …

Novartis image

Novartis reverses plant closure decision

January 18, 2012
Manufacturing and Production, Research and Development, Sales and Marketing Basel, Diovan, Novartis, Nyon, closure, job cuts

Novartis has said it will not close down a plant in Switzerland that had been due for closure, and has …

Novartis to cut 2,000 US jobs

January 13, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Diovan, Novartis, job cuts

Novartis will slash 1,960 jobs in the US as it prepares for life without its blockbuster medicine Diovan. The hypertension …

Takeda’s blood pressure treatment Edarbi approved

December 9, 2011
Sales and Marketing Diovan, Eisai, cardiovascular, high blood pressure, hypertension

Takeda’s new hypertension treatment Edarbi has been approved in Europe.Edarbi (azilsartan medoxomil) is a new once-daily angiotensin receptor blocker (ARB) …

European regulator probes ARB cancer link

June 28, 2010
Sales and Marketing ARB, Amias, Aprovel, Cozaar, Diovan, Micardis

European regulators have begun an investigation into a possible risk of cancer in patients taking angiotensin II receptor inhibitors for …

Tekturna fails to show heart attack benefit

March 17, 2010
Research and Development Diovan, Novartis, Tekturna, hypertension

Novartis’ hypertension treatment Tekturna has failed to show it helps patients recover from a heart attack when added to standard …

Latest content